We investigate the molecular recognition, aggregation inhibition, fibril disassembly, and membrane-protective mechanisms of small-molecule, peptide-based, and nanoscale inhibitors targeting disease-associated proteins and pathological aggregation. By integrating molecular simulation, computational screening, and experimental validation, we design and optimize candidate molecules and examine the relationship between anti-amyloid activity and cytotoxicity, including strategies to decouple the two.
